Abterra Bio Has Moved To Sorrento Valley
In 2009, Abterra Bio began as Digital Proteomics LLC, a spin-out of the University of California – San Diego. Founders Pavel Pevzner and Vineet Bafna, as well as Natalie Castellana, Stefano Bonissone, and Anand Patel have been a part of Abterra’s story since its inception.
Our employees fine-tuned the technology for antibody sequencing and discovery, and as we started to hire more people, we outgrew our first location: a shared lab bench in a biotech start-up incubator. In 2020 with 6 employees, we moved to the San Diego Science Center, our first real office and lab that we could call our own. We invested in a Thermo Fisher Orbitrap Eclipse mass spectrometer to expand our throughput and add capabilities to our services to customers looking for antibody discovery, sequencing, and repertoire analysis. Throughout our time there, we continued to grow (See the Abterra team now), and eventually traded that office for yet another larger one.
Our current chapter has begun in our new Sorrento Valley office and we couldn’t be more excited. We’re enjoying our state-of-the-art lab, multiple floors of offices, and even a conference room! At first we wondered, “Is this too much?” but after some reflection, realized how hard we have worked to get here. We’ve already begun filling the lab with new equipment, including a new sequencer that quadruples our NGS sequencing throughput. Our new space provides the room to grow our team and our capabilities for our valued customers.
If you’re considering a project with us, we’d love to talk to you.
Related Posts
Polyclonal Antibody Sequencing in Camelids
Serum contains circulating antibodies with unique functional properties. This fundamental fact is why we choose to mine the serum over cells - despite being more challenging. Here we compare the two approaches for polyclonal antibody sequencing available at Abterra...
Rabbit Polyclonal Antibody Sequencing for Neurodegenerative Disease Research
Rabbit polyclonal antibodies are commonly used reagents across biotech and academia. As of 2024, 43% of commercial catalog antibodies are polyclonals, and 66% of those are rabbit derived. Hyperimmunized rabbits consistently generate high affinity, target-specific...
Abterra Biosciences is a unique CRO offering antibody sequencing and discovery services. We bring sophisticated algorithmic and machine learning approaches to enable accurate antibody sequencing and functional antibody discovery.
Tell Us About Your Project
Follow Abterra Bio On Social Media
More From Our Blog
Rabbit Polyclonal Antibody Sequencing for Neurodegenerative Disease Research
Rabbit polyclonal antibodies are commonly used reagents across biotech and academia. As of 2024,...
De Novo Antibody Sequencing NISTmAb with Post-Translational Modification Detection
Protein sequencing has been possible for 75 years with Edman degradation, but over the past...
Monoclonal versus Polyclonal Antibody Sequencing
Antibody reagents used in biomedical research and diagnostics assays fall into two large...

